Results
Title

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Authors

Stathis, Anastasios; Tolcher, Anthony W.; Wang, Judy S.; Renouf, Daniel J.; Chen, Lin-Chi; Suttner, Leah H.; Freshwater, Tomoko; Webber, Andrea L.; Nayak, Tapan; Siu, Lillian L.

Publication

Investigational New Drugs, 2023, Vol 41, Issue 3, p380

ISSN

0167-6997

Publication type

Academic Journal

DOI

10.1007/s10637-022-01326-3